Drug intelligence / Profile preview

TR4

Development stage: Phase 1
Lead developer: Trio Medicines
Modality: Small Molecules

Overview

TR4 is a highly selective β2-adrenergic receptor antagonist developed by Trio Medicines Ltd. It is a small molecule drug designed to block the β2-adrenergic receptor, which distinguishes it from currently available beta-blockers that are either selective for the β1-adrenergic receptor or non-selective. Preclinical studies suggest that selective inhibition of the β2-adrenergic receptor may offer therapeutic benefits in chronic heart failure, chronic asthma, and potentially pancreatic cancer. The drug is currently in Phase 2 clinical trials for asthma and heart failure[1][2].

Targets

ADRB2 (β2)

Beyond the preview

Go deeper on TR4.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on TR4.

Explore the full profile